Insights
Insights From Our Experts
Articles
Rounding Up FDA’s Digital Health Actions from 2022 and Looking Forward to 2023
The healthcare sector continued the digitization evolution in 2022. Among the many product launches and technological advances, a recent report from AMA showed that 93% of physicians now see digital health tools as advantageous to patient…
8 Healthtech Trends For 2023
2023 is here, and with it comes foreshadowing of what the year will bring. In the life sciences and pharmaceutical industry, it’s not different. In fact, many have already made their predictions for the new year,…
Pivot Pros: How EVERSANA Course Corrected When the Market Changed
Traditional commercialization models lack the insights, flexibility and agility to synthesize and react to real-time data. If you needed to quickly pivot your strategy to ensure the success of your therapy in market, would your commercialization…
Adult Vaccine Landscape in APAC: The Need for Change
Content for this article was contributed by EVERSANA’s Asia Pacific team. Do Adults Need Vaccines? Immunization should not end with adulthood. Using immunization to prevent infection should be a life-long process, as adult vaccination provides benefits…
Invisible Orchestration: How Behind-the-Scenes Collaboration of Patient Services and Field Deployment Teams Delivers a Seamless Front-of-House Brand Experience
Providing services to patients in a digital world requires a delicate balance of blending high-tech and high-touch solutions. A majority of patients want the option to guide their own treatment journeys with ease and on their…
Seven Important Factors for APAC Companies to Consider while Launching Products in the Digital Health and Digital Therapeutics Space
Digital health and digital therapeutics innovation, commercialization, and adoption is accelerating in the APAC region. Digital medicines as an area, globally, is not new, yet even the largest players in the sector can still be considered…
Access Challenges for Severe Infectious Diseases
Content for this article was provided by EVERSANA’s Asia Pacific team. The global burden of infectious diseases is increasing, especially for severe diseases such as invasive aspergillosis, a rare infectious disease, which has a 90% mortality…
Ready or Not, Biosimilar Adalimumab Brings the Heat in 2023
Anticipated Growth in U.S. Biosimilars Market U.S. payers and other healthcare stakeholders have eagerly awaited the launch of biosimilar alternatives to high-cost originator products as a new cost-control lever. However, much of the U.S. healthcare market…
Case Study: Benchmarking Pathway-Specific Engagement with Health Plans & Organized Providers to Identify Best Practices
Tapping into primary market research and subject matter expertise can help uncover opportunities to more effectively meet their needs and position your brand for inclusion within their pathways. As stakeholders seek to leverage oncology clinical pathways…
Establishing the Patient Access Mission During Clinical Development
An inescapable but disappointing characteristic of pharmaceutical research and development is that at the end of a process costing billions of dollars, the majority of launches fail to reach expectations. The ultimate tragedy of this is…